An Inflammatory Cytokine Milieu is Prominent in Premalignant Oral Lesions, but Subsides when Lesions Progress to Squamous Cell Carcinoma.
about
Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.Chronic Inflammation-Related HPV: A Driving Force Speeds Oropharyngeal Carcinogenesis.Cytokine and Adipokine Levels in Patients with Premalignant Oral Lesions or in Patients with Oral Cancer Who Did or Did Not Receive 1α,25-Dihydroxyvitamin D3 Treatment upon Cancer Diagnosis.Indomethacin Treatment of Mice with Premalignant Oral Lesions Sustains Cytokine Production and Slows Progression to Cancer.Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine.Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.Th17 Cells in Protection from Tumor or Promotion of Tumor ProgressionRedirecting the focus of cancer immunotherapy to premalignant conditions.Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation.T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma.Salivary Immunosuppressive Cytokines IL-10 and IL-13 Are Significantly Elevated in Oral Squamous Cell Carcinoma Patients.Role of IL-23 signaling in the progression of premalignant oral lesions to cancer.Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.
P2860
Q33832752-4624FF0F-B8DE-41C6-8339-9A10D6B60984Q35699802-8D964F89-F2E4-40F5-B8B7-D6B8B0495DBBQ36102797-733A8025-C8BC-4DF0-9426-594423621CD5Q37273566-F6EEE28F-65AF-42EA-A649-8643740AFA1EQ37274307-952B29D6-7BFA-4341-BABF-80D0B7055070Q37286424-4D7A556A-8DAE-427E-B60D-7506A4153A44Q37664203-92904F73-5B9F-4DBD-911A-032B47DE5948Q38907336-DC43AE97-CC58-40CC-ADAD-BD7325CC6994Q39107022-EDC4708B-F77F-46AC-B682-B42B3424864CQ41850484-C26A2411-9DBB-4C93-812C-BB75AEA68040Q42365249-FA6E10B3-52B9-48D9-8AD4-239988380F57Q53109856-440AA010-3F2E-434E-B725-8F7941FD456DQ53478215-5E6B78EB-A2C1-4D5E-AC95-9111FE86B05EQ55265890-6B588046-CB88-4341-B3FC-1763096143ABQ55295766-1ECED353-EC1F-464F-A5A0-63F31B7520CD
P2860
An Inflammatory Cytokine Milieu is Prominent in Premalignant Oral Lesions, but Subsides when Lesions Progress to Squamous Cell Carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@ast
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@en
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@nl
type
label
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@ast
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@en
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@nl
prefLabel
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@ast
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@en
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@nl
P2093
P2860
P1476
An Inflammatory Cytokine Milie ...... ss to Squamous Cell Carcinoma.
@en
P2093
Anna-Maria A De Costa
Danielle Woodford
M Rita I Young
Sara D Johnson
P2860
P356
10.4172/2155-9899.1000230
P577
2014-06-01T00:00:00Z